RecruitingPHASE1, PHASE2NCT06255782
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Studying Ornithine transcarbamylase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- iECURE, Inc.
- Principal Investigator
- George Diaz, M.D., Ph.DiECURE, Inc.
- Intervention
- ECUR-506(genetic)
- Enrollment
- 20 enrolled
- Eligibility
- MALE
- Timeline
- 2024 – 2026
Study locations (10)
- UCLA Mattel Children's Hospital, Los Angeles, California, United States
- Children's Hospital of Colorado, Anshutz Medical Campus, Aurora, Colorado, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- The Children's Hospital at Westmead, Sydney, New South Wales, Australia
- The Royal Children's Hospital, Melbourne, Victoria, Australia
- Hopsital Sant Joan de Deu, Barcelona, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Great Ormond Street Hospital, London, United Kingdom
- The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06255782 on ClinicalTrials.govOther trials for Ornithine transcarbamylase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06805695Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)iECURE, Inc.
- RECRUITINGPHASE2NCT06488313A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCDArcturus Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT05092685Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEnUniversity College, London
- ACTIVE NOT RECRUITINGPHASE3NCT05345171Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) DeficiencyUltragenyx Pharmaceutical Inc
- RECRUITINGNCT04908319Hepatic Histopathology in Urea Cycle DisordersBaylor College of Medicine
- ACTIVE NOT RECRUITINGNCT04612764Liver Disease in Urea Cycle DisordersBaylor College of Medicine
- ACTIVE NOT RECRUITINGNCT03636438Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC DeficiencyUltragenyx Pharmaceutical Inc